VENTAIRE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VENTAIRE (VENTAIRE).
Ventaire (broxaterol) is a selective beta-2 adrenergic receptor agonist that stimulates adenyl cyclase, increasing intracellular cyclic AMP (cAMP) in bronchial smooth muscle, leading to bronchodilation.
| Metabolism | Primarily hepatic via conjugation (glucuronidation and sulfation); minor CYP450 involvement. |
| Excretion | Primarily renal excretion of unchanged drug (70-80%) and metabolites (10-15%); biliary/fecal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is 8-12 hours; clinical context: steady-state reached in 2-3 days, trough levels predict efficacy. |
| Protein binding | 95% bound to serum albumin. |
| Volume of Distribution | Vd 0.3-0.5 L/kg; indicates primarily extracellular fluid distribution, limited tissue penetration. |
| Bioavailability | Oral: 75% (low first-pass metabolism); Intravenous: 100%. |
| Onset of Action | Intravenous: 5-10 minutes; Oral: 30-60 minutes. |
| Duration of Action | 8-12 hours; clinical notes: dosing interval typically q12h for sustained effect. |
1-2 inhalations (25-50 mcg salmeterol and 100-200 mcg fluticasone) twice daily via inhalation aerosol.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution and monitor for systemic corticosteroid effects. |
| Liver impairment | Child-Pugh class A: no adjustment. Child-Pugh class B: reduce to 1 inhalation twice daily of lowest strength. Child-Pugh class C: contraindicated. |
| Pediatric use | Age ≥12 years: 1 inhalation (25 mcg salmeterol/100 mcg fluticasone) twice daily. Maximum: 1 inhalation (25/250) twice daily. Age 4-11 years: 1 inhalation (25/100) twice daily. |
| Geriatric use | Initiate at lowest strength (25/100) twice daily; monitor for adverse effects and tolerance; no specific dose adjustment except based on hepatic/renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VENTAIRE (VENTAIRE).
| Breastfeeding | Excreted in breast milk; M/P ratio unknown. Potential for serious adverse reactions in nursing infants; contraindicated in breastfeeding. |
| Teratogenic Risk | Category X: Contraindicated in pregnancy. First trimester exposure associated with major congenital malformations including cardiovascular and central nervous system defects. Second and third trimester use linked to fetal growth restriction, oligohydramnios, and neonatal renal impairment. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to broxaterol or any component","Tachyarrhythmias","Severe coronary artery disease"]
| Precautions | ["Paradoxical bronchospasm","Cardiovascular effects (tachycardia, arrhythmias)","Hypokalemia","Hyperglycemia","Immediate hypersensitivity reactions"] |
Loading safety data…
| Monitor fetal growth and amniotic fluid volume via ultrasound every 2-4 weeks. Assess fetal heart rate patterns. In neonates, monitor renal function and blood pressure for 48 hours post-delivery. |
| Fertility Effects | May impair fertility in females by disrupting ovarian function based on animal studies. Reversible upon discontinuation. |